Multiple Myeloma, Refractory Clinical Trial
Official title:
A Phase II Study of Pembrolizumab, Belantamab and Dexamethasone in Patients With Triple Class Refractory Multiple Myeloma.
This is a single arm, multi-institution (1) Hackensack Meridian Health at Hackensack, New Jersey (NJ) (2) Jersey Shore Medical Center, Neptune, NJ and (3) Georgetown/Lombardi Cancer Center) phase II study of the combination of pembrolizumab, belantamab, and dexamethasone in patients with triple class refractory multiple myeloma.
This is a single arm, multi-institution (1) Hackensack Meridian Health at Hackensack, NJ (2) Jersey Shore Medical Center, Neptune, NJ and (3) Georgetown/Lombardi Cancer Center) phase II study of the combination of pembrolizumab, belantamab, and dexamethasone in patients with triple class refractory multiple myeloma. All institutions will share the same Institutional Review Board. Safety lead-in Cohort: After the first 10 patients are enrolled, an independent safety review committee will meet to review adverse events and toxicity and determine whether the trial will continue to enroll. Phase 2 portion: The remainder of patients will be enrolled using a Simon's - 2 stage design. The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05008536 -
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma
|
Early Phase 1 | |
| Recruiting |
NCT06158412 -
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT05121103 -
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04603872 -
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
|
Early Phase 1 | |
| Recruiting |
NCT04657861 -
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
|
Early Phase 1 | |
| Terminated |
NCT05191472 -
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
|
Phase 2 | |
| Active, not recruiting |
NCT04688853 -
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients
|
Phase 1 | |
| Not yet recruiting |
NCT05050305 -
Marizomib Central Nervous System (CNS)
|
Phase 2 | |
| Recruiting |
NCT05546723 -
LMY-920 for Treatment of Relapsed or Refractory Myeloma
|
Phase 1 | |
| Not yet recruiting |
NCT06225310 -
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
|
Phase 1 | |
| Not yet recruiting |
NCT06115135 -
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT05673083 -
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
|
||
| Completed |
NCT02176213 -
Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
| Enrolling by invitation |
NCT04861480 -
Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT06012383 -
Alvocade® (Bortezomib) Safety and Effectiveness Study
|
||
| Not yet recruiting |
NCT05909826 -
Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
|
Phase 2 | |
| Recruiting |
NCT04414475 -
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM
|
Phase 2 | |
| Completed |
NCT04811898 -
A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment
|
Phase 1 | |
| Recruiting |
NCT05739188 -
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05747586 -
BCMA CAR-NK For Patients With RRMM
|
N/A |